Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot study

Journal of Cystic Fibrosis

Volumn 6, Issue 4, 2007, Pages 284-292

  Westerman, E M ^a,b   De Boer, A H ^c   Le Brun, P P H ^a,b   Touw, D J ^a,b   Roldaan, A C ^b   Frijlink, H W ^c   Heijerman, H G M ^b  

^a Apotheek Haagse Ziekenhuizen   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Colistin; Cystic fibrosis; Dry powder inhalation; Twincer inhaler

Indexed keywords

COLISTIMETHATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CHEST INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG LABELING; DRUG TOLERABILITY; DRY POWDER; FEASIBILITY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG FUNCTION TEST; MALE; NEBULIZER; OPEN STUDY; OUTPATIENT CARE; PARTICLE SIZE; PILOT STUDY; POWDER INHALER; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, INHALATION; ADULT; ANTI-BACTERIAL AGENTS; COLISTIN; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY FLOW RATES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PILOT PROJECTS; POWDERS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 34250899751     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2006.10.010     Document Type: Article

References (42)

1. Döring G., Conway S.P., Heijerman H.G.M., Hodson M.E., Høiby N., Smyth A., et al., Consensus Committee. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16 (2000) 749-767
2. Le Brun P.P.H., de Boer A.H., Heijerman H.G.M., and Frijlink H.W. A review of the technical aspects of drug nebulization. Pharm World Sci 22 (2000) 75-81
3. Brand P., Meyer T., Haussermann S., Schulte M., Scheuch G., Bernhard T., et al. Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med 18 (2005) 45-54
4. Laube B.L., Jashnani R., Dalby R.N., and Zeitlin P.L. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 118 (2000) 1069-1076
5. Kettler L.J., Sawyer S.M., Winefield H.R., and Greville H.W. Determinants of adherence in adults with cystic fibrosis. BMJ (2002) 459-464
6. Hutchinson G.R., Parker S., Pryor J.A., Duncan-Skingle F., Hoffman P.N., Hodson M.E., et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 34 (1996) 584-587
7. Standaert T.A., Morlin G.L., Williams-Warren J., Joy P., Pepe M.S., Weber A., et al. Effect of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest 114 (1998) 577-586
8. Hurley P.K., Smye S.W., and Cunliffe H. Assessment of antibiotic aerosol generation using commercial jet nebulizers. J Aerosol Med 7 (1994) 217-228
9. McCallion O.N.M., Taylor K.M.G., Bridges P.A., Thomas M., and Taylor A.J. Jet nebulisers for pulmonary drug delivery. Int J Pharm 130 (1996) 1-11
10. Ferron G.A., Busch B., Gebhart J., and Roth C. Evaporation of aerosols produced with eleven jet nebulizers. J Aerosol Sci 27 (1996) S381-S382
11. Coates A.L., MacNeish C.F., Meisner D., Kelemen S., Thibert R., MacDonald J., et al. The choice of a jet nebulizer, nebulising flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 111 (1997) 1206-1212
12. Le Brun P.P.H., de Boer A.H., Gjaltema D., Hagedoorn P., Heijerman H.G.M., and Frijlink H.W. Inhalation of tobramycin in cystic fibrosis part 1: the choice of a nebulizer. Int J Pharm 189 (1999) 205-214
13. Ho S.L., Kwong W.T.J., O'Drowsky L., and Coates A.L. Evaluation of four breath-enhanced nebulizers for home use. J Aerosol Med 14 (2001) 467-475
14. Katz S.L., Ho S.L., and Coates A.L. Nebulizer choice for inhaled colistin treatment in cystic fibrosis. Chest 119 (2001) 250-255
15. Standaert T.A., Bohn S.E., Aitken M.L., and Ramsey B. The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics. J Aerosol Med 14 (2001) 31-41
16. De Boer A.H., Hagedoorn P., and Frijlink H.W. The choice of a compressor for the aerosolisation of tobramycine (TOBI) with the PARI LC PLUS reusable nebuliser. Int J Pharm 268 (2003) 59-69
17. Frijlink H.W., and de Boer A.H. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 1 (2004) 67-86
18. Rau J.L. The inhalation of drugs: advantages and problems. Respir Care 50 (2005) 367-382
19. Telko M.J., and Hickey A.J. Dry powder inhaler formulation. Respir Care 50 (2005) 1209-1227
20. ®) for high powder doses. Eur J Pharm Sci 28 (2006) 171-178
21. Bates D.V., Fish B.R., Hatch T.F., Mercer T.T., and Morrow P.E. Deposition and retention models for internal dosimetry of the human respiratory tract. Task group on lung dynamics. Health Phys 12 (1966) 173-207
22. Zanen P., Go L.T., and Lammers J.W. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51 (1996) 977-980
23. Sarinas P.S., Robinson T.E., Clark A.R., Canfield J., Chitkara R.K., and Fick R.B. Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases. Chest 114 (1998) 988-992
24. Newhouse M.T., Hirst P.H., Duddu S.P., Walter Y.H., Tarara T.E., Clark A.R., et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 124 (2003) 360-366
25. Crowther Labiris N.R., Holbrook A.M., Chrystyn H., MacLeod S.M., and Newhouse M.T. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. Am J Respir Crit Care Med 160 (1999) 1711-1716
26. Goldman J.M., Bayston S.M., O'Connor S., and Meigh R.E. Inhaled micronised gentamicin powder: a new delivery system. Thorax 45 (1990) 939-940
27. Le Brun P.P.H., de Boer A.H., Mannes G.P.M., de Fraîture D.M.I., Brimicombe R.W., Touw D.J., et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 54 (2002) 25-32
28. Westerman EM, de Boer AH, Le Brun PPH, Touw DJ, Frijlink HW, Heijerman HGM. Dry powder inhalation of colistin in healthy volunteers: a pilot study. Int J Pharm, in press; doi:10.1016/j.jcf.2006.10.010.
29. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
30. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 6 Suppl 16 (1999) 5-40
31. Le Brun P.P.H., de Graaf A.I., and Vinks A.A.T.M.M. High-performance liquid chromatographic method for the determination of colistin in serum. Ther Drug Monit 5 (2000) 589-593
32. Proost J.H., and Meijer D.K.F. MWPharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22 (1992) 155-163
33. Newman S.P. Deposition and effects of inhalation aerosols. AB DRACO Lund Sweden (1983) 13-22
34. O'Callaghan C., and Barry P.W. The science of nebulised drug delivery. Thorax 52 Suppl 2 (1997) S31-S44
35. Touw D.J., Jacobs F.A.H., Brimicombe R.W., Heijerman H.G.M., Bakker W., and Breimer D.D. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 41 (1997) 184-187
36. Le Brun P.P.H., Vinks A.A.T.M.M., Touw D.J., Hekelaar N., Mannes G.P.M., Brimicombe R.W., et al. Can tobramycin inhalation be improved with a jet nebulizer?. Ther Drug Monit 21 (1999) 618-624
37. de Boer A.H., Le Brun P.P.H., van der Woude H.G., Hagedoorn P., Heijerman H.G.M., and Frijlink H.W. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur J Pharm Biopharm 54 (2002) 17-24
38. Westerman E.M., Le Brun P.P.H., Touw D.J., Frijlink H.W., and Heijerman H.G.M. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros 3 (2004) 23-28
39. Cochrane M.G., Bala M.V., Downs K.E., Mauskopf J., and Ben-Joseph R.H. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 117 (2000) 542-550
40. Aswania O., Ritson S., Iqbal S.M., Bhatt J., Rigby A.S., and Everard M.L. Intra-subject variability in lung dose in healthy volunteers using five conventional portable inhaler. J Aerosol Med 17 (2004) 231-238
41. Patton J.S. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 19 (1996) 3-36
42. Tronde A., Norden B., Marchner H., Wendel A.K., Lennernas H., and Bengtsson U.H. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci 92 (2003) 1216-1233